Medical College of Wisconsin (MCW) has announced the founding of Rose Biosciences, a biotech company pioneering a new approach to obesity treatment based on a discovery at MCW.
Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.
Researchers from the University of Coimbra presented data from a study that aimed to assess the role of the ghrelin/neuropeptide Y (NPY) system in adipose tissue in subjects with obesity and metabolic syndrome.
Researchers from the University of Zurich presented data from a study that aimed to investigate the impact of liver-specific apoptosis signal regulating kinase 1 (ASK1) overexpression on the development of high-fat diet (HFD)-induced obesity and impaired glucose metabolism.
Deciduous Therapeutics Inc. has disclosed compounds with the ability to activate invariant natural killer T cells (iNKT) and that are reported to be useful for the treatment of obesity.
Les Laboratoires Servier SAS has divulged new glucagon-like peptide (GLP-1) receptor agonists reported to be useful for the treatment of obesity and diabetes.
Impairment in the functionality of the adipose tissue is crucial for obesity-related metabolic comorbidities and may trigger the onset of type 2 diabetes. The adipose tissue has been proposed as a main contributor of circulating miRNAs (miRNAs), but has not yet been characterized for these markers.
